The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

Liang Cheng, Shaobo Zhang, Riley Alexander, Yongxue Yao, Gregory T. MacLennan, Chong-Xian Pan, Jiaoti Huang, Mingsheng Wang, Rodolfo Montironi, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Two classes of anti-EGF receptor (EGFR) agents, monoclonal anti-EGFR antibodies and small-molecule EGFR tyrosine kinase inhibitors, have been used for the treatment of non-small-cell lung cancer (NSCLC). However, only a subset of patients will benefit from EGFR-targeted therapy. The discovery of biomarkers that select the appropriate patients for the therapy and predict the responses to the therapy is urgently needed. Molecular genetic analyses provide new insights into EGFR pathway alterations and demonstrate promise for predicting the clinical outcome of patients with NSCLC. In this article, we summarize the latest available knowledge on the clinical impact of EGFR mutations, gene copy number, EGFR overexpression, phosphorylation expression and the alteration of the EGFR pathway downstream factors in predicting the response to EGFR-targeted therapy in NSCLC patients. The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.

Original languageEnglish (US)
Pages (from-to)519-541
Number of pages23
JournalFuture Oncology
Volume7
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Therapeutics
Mutation
Gene Dosage
Protein-Tyrosine Kinases
Molecular Biology
Lung Neoplasms
Biomarkers
Phosphorylation
Antibodies

Keywords

  • EGF receptor
  • EML4-ALK
  • FISH
  • lung cancer
  • molecular genetic pathology
  • non-small-cell lung cancer
  • personalized medicine
  • targeted therapy
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cheng, L., Zhang, S., Alexander, R., Yao, Y., MacLennan, G. T., Pan, C-X., ... Lopez-Beltran, A. (2011). The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology, 7(4), 519-541. https://doi.org/10.2217/fon.11.25

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. / Cheng, Liang; Zhang, Shaobo; Alexander, Riley; Yao, Yongxue; MacLennan, Gregory T.; Pan, Chong-Xian; Huang, Jiaoti; Wang, Mingsheng; Montironi, Rodolfo; Lopez-Beltran, Antonio.

In: Future Oncology, Vol. 7, No. 4, 04.2011, p. 519-541.

Research output: Contribution to journalArticle

Cheng, L, Zhang, S, Alexander, R, Yao, Y, MacLennan, GT, Pan, C-X, Huang, J, Wang, M, Montironi, R & Lopez-Beltran, A 2011, 'The landscape of EGFR pathways and personalized management of non-small-cell lung cancer', Future Oncology, vol. 7, no. 4, pp. 519-541. https://doi.org/10.2217/fon.11.25
Cheng, Liang ; Zhang, Shaobo ; Alexander, Riley ; Yao, Yongxue ; MacLennan, Gregory T. ; Pan, Chong-Xian ; Huang, Jiaoti ; Wang, Mingsheng ; Montironi, Rodolfo ; Lopez-Beltran, Antonio. / The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. In: Future Oncology. 2011 ; Vol. 7, No. 4. pp. 519-541.
@article{7eab3ed369dd44619f60bfdbf775a4c2,
title = "The landscape of EGFR pathways and personalized management of non-small-cell lung cancer",
abstract = "Two classes of anti-EGF receptor (EGFR) agents, monoclonal anti-EGFR antibodies and small-molecule EGFR tyrosine kinase inhibitors, have been used for the treatment of non-small-cell lung cancer (NSCLC). However, only a subset of patients will benefit from EGFR-targeted therapy. The discovery of biomarkers that select the appropriate patients for the therapy and predict the responses to the therapy is urgently needed. Molecular genetic analyses provide new insights into EGFR pathway alterations and demonstrate promise for predicting the clinical outcome of patients with NSCLC. In this article, we summarize the latest available knowledge on the clinical impact of EGFR mutations, gene copy number, EGFR overexpression, phosphorylation expression and the alteration of the EGFR pathway downstream factors in predicting the response to EGFR-targeted therapy in NSCLC patients. The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.",
keywords = "EGF receptor, EML4-ALK, FISH, lung cancer, molecular genetic pathology, non-small-cell lung cancer, personalized medicine, targeted therapy, tyrosine kinase inhibitor",
author = "Liang Cheng and Shaobo Zhang and Riley Alexander and Yongxue Yao and MacLennan, {Gregory T.} and Chong-Xian Pan and Jiaoti Huang and Mingsheng Wang and Rodolfo Montironi and Antonio Lopez-Beltran",
year = "2011",
month = "4",
doi = "10.2217/fon.11.25",
language = "English (US)",
volume = "7",
pages = "519--541",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

AU - Cheng, Liang

AU - Zhang, Shaobo

AU - Alexander, Riley

AU - Yao, Yongxue

AU - MacLennan, Gregory T.

AU - Pan, Chong-Xian

AU - Huang, Jiaoti

AU - Wang, Mingsheng

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

PY - 2011/4

Y1 - 2011/4

N2 - Two classes of anti-EGF receptor (EGFR) agents, monoclonal anti-EGFR antibodies and small-molecule EGFR tyrosine kinase inhibitors, have been used for the treatment of non-small-cell lung cancer (NSCLC). However, only a subset of patients will benefit from EGFR-targeted therapy. The discovery of biomarkers that select the appropriate patients for the therapy and predict the responses to the therapy is urgently needed. Molecular genetic analyses provide new insights into EGFR pathway alterations and demonstrate promise for predicting the clinical outcome of patients with NSCLC. In this article, we summarize the latest available knowledge on the clinical impact of EGFR mutations, gene copy number, EGFR overexpression, phosphorylation expression and the alteration of the EGFR pathway downstream factors in predicting the response to EGFR-targeted therapy in NSCLC patients. The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.

AB - Two classes of anti-EGF receptor (EGFR) agents, monoclonal anti-EGFR antibodies and small-molecule EGFR tyrosine kinase inhibitors, have been used for the treatment of non-small-cell lung cancer (NSCLC). However, only a subset of patients will benefit from EGFR-targeted therapy. The discovery of biomarkers that select the appropriate patients for the therapy and predict the responses to the therapy is urgently needed. Molecular genetic analyses provide new insights into EGFR pathway alterations and demonstrate promise for predicting the clinical outcome of patients with NSCLC. In this article, we summarize the latest available knowledge on the clinical impact of EGFR mutations, gene copy number, EGFR overexpression, phosphorylation expression and the alteration of the EGFR pathway downstream factors in predicting the response to EGFR-targeted therapy in NSCLC patients. The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed.

KW - EGF receptor

KW - EML4-ALK

KW - FISH

KW - lung cancer

KW - molecular genetic pathology

KW - non-small-cell lung cancer

KW - personalized medicine

KW - targeted therapy

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79953673890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953673890&partnerID=8YFLogxK

U2 - 10.2217/fon.11.25

DO - 10.2217/fon.11.25

M3 - Article

C2 - 21463141

AN - SCOPUS:79953673890

VL - 7

SP - 519

EP - 541

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -